Insilico cuts drug discovery to 9 months but relies on China

insilico medicine has compressed the time to produce drug development candidates to approximately one year, with its fastest program achieving candidate nomination in just nine months. by combining generative ai with physical laboratory operations in china, the hong kong-listed company significantly undercuts the typical 13-month timeline. this efficiency demonstrates the tangible impact of ai on biotech speed, challenging established pharmaceutical r&d models. the success suggests that integrated ai-lab workflows could become the industry standard, potentially reshaping global competitive dynamics in drug discovery.